PATH-28. DIFFERENCES IN METHYLATION PROFILES BETWEEN LONG-TERM SURVIVORS AND SHORT-TERM SURVIVORS OF IDH WILD-TYPE GLIOBLASTOMA. (14th November 2022)

• Record Type: Journal Article
• Authors: van der Meulen, Matthijs; Ramos, Ronald; Voisin, Mathew; Patil, Vikas; Wei, Qingxia; Singh, Olivia; Climans, Seth; Kalidindi, Navya; Or, Rosamarylin; Diamandis, Phideas; Munoz, David; Zadeh, Gelareh; Mason, Warren
• Is Part Of: Neuro-oncology. Volume 24(2022)Supplement 7
• Page Start: vii156
• Page End: vii156
• Publication Date: 2022-11-14
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noac209.601
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: INTRODUCTION: Patients with glioblastomas (GBM) have an overall survival (OS) of approximately 15 months. However, approximately 5% of patients survive much longer, with an OS of > 5 years. This study examines the differences in methylation profiles between long-term survivors ( > 5 years, LTS) and short-term survivors (< 1 year, STS) with an isocitrate dehydrogenase (IDH) wild-type GBM. METHODS: In a multicenter retrospective analysis, we identified 25 long-term survivors with a histologically confirmed GBM. These were age and sex-matched to a short-term survivor. The methylation profiles of all 50 samples were analyzed with EPIC 850k, classified according to the DKFZ methylation classifier, and the methylation profiles of all IDH wild-type LTS vs STS were compared. RESULTS: After methylation profiling, 16/25 LTS and 23/25 STS were confirmed to be IDH wild-type GBMs, all with copy number gains of chromosome 7 and loss of chromosome 10. There were no significant differences between tumour purity or GBM subtype between LTS and STS. LTS had significantly increased MGMT promoter methylation (p = 0.01), and higher FGFR3-TACC3 (p = 0.03), compared to STS. STS had significantly more often a CDKN2A/B loss (p = 0.01) and higher levels of NF1 (p = 0.02), compared to LTS. There were no significant CpGs identified between LTS vs STS at an adjusted p-value of 0.05. Unadjusted analyses identified key pathways and biological processes involved in both LTS and STS. The top pathway in LTS was the Hippo signaling pathway and the Wnt pathway. The top pathway in STS was GPCR ligand binding and cell-cell signaling. CONCLUSION: A small group of patients with IDH wild-type GBM survive more than 5 years. While there are few differences in the global methylation profiles of long-term survivors compared to short-term survivors, our study highlights potential pathways involved in aggressive and senescent GBMs.